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Treacher Collins syndrome (TCS) is a rare autosomal dominant disorder characterized by craniofacial deformities. It is the most
common type of mandibulofacial dysostosis (MFD). The objective of this study is to do cytogenetic analysis of a TCS family.
Physical examination and all available medical records were reviewed. 50 GTG-banded metaphases were analysed to detect
any structural or numerical chromosomal abnormality. Downward slanting of palpebral ﬁssures, hypoplasia of zygomatic arch
complex, and hypoplasia of mandible were present in all. Cytogenetic ﬁndings show interstitial deletion in chromosomes 5(q32-
q33) and 3(q23–q25). We report four members of three generations of a family having TCS in a unique way that the deletion has
been found in 3q and 5q which has not been reported. Mosaicism of deletion on 5q was detected in all aﬀected members whereas
3q deletion was found only in one member (II.2). This ﬁnding may represent a more severe manifestation of the TCS. Thus the
evaluation and counselling of the TCS patients should be undertaken with caution.
1.Introduction
TCS is a rare genetic disorder characterised by craniofacial
deformities. It is named after Edward Treacher Collins
(1862–1932), the English surgeon and ophthalmologist who
described its essential traits in 1900. TCS is an autosomal
dominant disorder which has an incidence of approximately
1 in 50,000 still births [1]. This is a congenital malformation
involving dysmorphogenesis of ﬁrst and second branchial
arches which occurs between the 5th to 8th week of embry-
onic development [2]. There is no preference among the
genders or races. The clinical features of the TCS are usually
bilaterally symmetrical in nature. Mildly aﬀected individuals
are diﬃcult to diagnose because of the variable expressivity
of the gene; however, the gene is rarely nonpenetrant [3].
But the major diagnostic criteria of this disease include
antimongoloidslantofthepalpebralﬁssures, malarhypopla-
sia, malformation of the pinna, mandibular hypoplasia,
coloboma of the eyelid, micrognathia, microtia, conductive
deafness, and cleft palate [4, 5]. In severely aﬀected patients
the airway is compromised by the mandibular deﬁciency,
glossoptosis, and choanal atresia [6, 7].
ThelocusofTCSwasinitiallymappedtoa9cMregionon
chromosome 5q31–34 [3]. Subsequently, a ﬁne genetic and
radiation hybrid mapping helped in establishing a critical
region of <1Mb at 5q31.3–32 to be identiﬁed as TCS locus
[8–10]. The region contains the TCOF1 gene which codes
for a low-complexity protein, treacle composed of 1411
a m i n oa c i d s .T h i sp r o t e i np l a y saf u n d a m e n t a lr o l ei ne a r l y
embryonic development, particularly in the development of
craniofacial complex. The peak levels of expression of the
protein in the developing embryos were observed at the edge
of neural folds and in the branchial arches at the time of
critical morphogenetic events [11]. Treacle is considered as
the nucleolar localization signal binding protein that travels
on the track between cytoplasm and the nucleolus [12].2 Case Reports in Medicine
Mutations are spread throughout the gene, and 60% of the
TCS cases arise from de novo mutations [13]. The patients
with TCS were found to be heterozygous for mutation in
TCOF1 gene [14, 15].
Cytogenetic abnormalities have been useful in directing
attention to candidate region in craniofacial anomalies in
which the biochemical defect is not known. Chromosomal
location in these cases has also been proven successfully
through genetic linkage analysis [13, 16–19]. There are
several reports describing the patients with various chromo-
somal abnormalities suggesting additional loci for TCS on
chromosomes 3p23–24.12, 4p15.32–14, and 5q11 [20–22].
Thus the possibility exists that TCS can be caused by more
than one gene because recombination in aﬀected individuals
has been reported to preclude TCOF1 as the disease causing
gene located on 5q32-33 [23].
We report a family in which four members of three
generationsareaﬀectedwithTCS.Thechromosomalanalysis
oftheaﬀectedfamilymemberswasdoneusingGTG-banding
which revealed a unique concordanceof 3q and 5q deletions,
never reported earlier. Although the clinical features of all
the aﬀected members are similar but a new deletion has
been found in one member. This suggests that TCS locus
might be positioned at a locus other than 5q32-33 but the
chromosomal analysis of the other three members excluded
this possibility.
2.CasePresentation
2.1. Clinical Features. All aﬀected members had normal psy-
chomotordevelopmentand intelligence.Downward slanting
palpebral ﬁssures, hypoplasia of mandible, and hypoplasia
of zygomatic arches are the only clinical features present in
each aﬀected member whereas three out of four show partial
absence of lower eyelashes. None of the aﬀected members
had microphthalmia, epibulbar lipodermoid, upper or lower
lid coloboma, hair on the cheeks, microstomia, and choanal
atresia. Pedigree (Figure 1) showed the transmission of the
trait as autosomal dominant pattern. It showed two female
to female and one female to male transmission. There is
no signiﬁcant diﬀerence in clinical severity between the
aﬀected males and females. Phenotypic features of the
aﬀected members have been summarized in Table 1,a n dt h e
photographs of the aﬀected members have been shown in
Figures 2(a) and 2(b).
2.2. Cytogenetic Evaluation
2.2.1. Chromosome Preparation [24]. Chromosomal analysis
was done in TCS patients to identify for the presence of
any numerical or structural chromosomal aberrations. For
this lymphocyte cultureswere setup, and chromosomes were
analyzed by G-banding. Five mL of heparinized blood was
drawn and kept in an upright position at 37◦Cf o r3 0
minutes. This helps in the separation of plasma from red
blood cells. Then, the plasma and the settled lymphocyte
(PLS, plasma lymphocyte suspension) in buﬀy coat tapped
gently and mixed together. The needle was bent, and 0.5mL
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Figure 1: Pedigree showing the autosomal dominant pattern of
inheritance of TCS in the family.
Table 1: Phenotypic features of the aﬀected family members.
Aﬀected members II.2 III.3 IV.2 IV.1
Sex/age F/55 F/30 F/4 M/3
Downward slanting palpebral ﬁssures + + + +
Lower lid coloboma −− − −
Hypoplasia of zygomatic complex + + + +
Microtia + − ++
Atresia of external ear canal −− ++
Cleft palate −− ++
Conductive deafness + − ++
Choanal atrasia −− − −
Pre-auricular tags −− ++
Delayed speech development + + + +
Antimongoloidstout + − ++
Ear pinna deformed −− ++
Micrognathia + + + −
Partial absence of lower eyelash − ++ +
Facial phenotype Mild Mild Severe Severe
of PLS was transferred into a sterile culture vial containing
5mL ofmedia RPMI-1640 and 0.2mL Phytohaemagglutinin
(PHA). The cultures were incubated for 72 hours at 37◦C.
After 70 hours of incubation, 0.1mL (0.2%) of colcemid
was added to the cultures. At 72 hours the samples were
washed for removing colcemid. Then, they were centrifuged
at a speed of 1000rpm for 10 minutes, the supernatant
was discarded, and freshly prepared pre-warmed hypotonic
solution (0.56% KCl) was added and incubated for 20–25
minutes at 37◦C. The cell suspension centrifuged again, and
after discarding the supernatant, freshly prepared chilled
carnoy’s ﬁxative (methanol:acetic acid/3:1) was added to
the cell pellet slowly. At least three changes of ﬁxative were
giventill thepellet became pale.Two dropsofcell suspension
were dropped from a height on a clean wet slide.
2.2.2. G-Banding [25]. Giemsa staining of chromosome
preparation after proteolytic enzyme treatment revealed G-
banding. The 3-day old matured unstained chromosome
preparations were ﬂooded with 0.25% trypsin for 10–15
seconds, then the slides were rinsed in phosphate buﬀer
saline. The slides were stained in 2% Giemsa stain forCase Reports in Medicine 3
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Figure 2: (a) Showing the phenotypes of the eﬀected members (front view). (b) Showing the phenotypes of the eﬀected members (side
view).
Table 2:Mosaicismofdeletions 5qand3qin theaﬀected members.
Aﬀected members Karyotype %
II.2 46,XX 60
46,XXdel(5q32-33) 30
46,XXdel(3q23–25) 10
III.3 46,XX 53
46,XXdel(5q32-33) 47
IV.1 46,XY 45
46,XYdel(5q32-33) 55
IV.2 46,XX 60
46,XXdel(5q32-33) 40
5–7 minutes, thereafter, they were washed in distilled
water. Metaphases were analyzed using cytovision software
(zeiss microscope) classiﬁed according to ISCN 1995. At
least 50 metaphases in each patient were analyzed and
karyotyped.
Cytogenetic studies of peripheral blood lymphocytes
showed mosaicism with an interstitial deletion of 3q and 5q.
Using 400–450 band level GTG banding, the deleted portion
was found to be at 3q23–25 and 5q32-33. Karyotype of the
proband (IV.1) (Figure 3(d)) is 46,XY,del(5)(q32-33). The
karyotypeofhis mother(III.3)(Figure 3(a)) and sister (IV.2)
(Figure 3(c)) also showed deletion in chromosome 5 only.
The chromosomal complement of the grandmother (II.2)
(Figure 3(b)) showed deletion in both 3q and 5q, karyotype
46,XX,del(5)(q32-33)del(3q)(q23–25).Mosaicism of 3q and
5q deletion in aﬀected members has been summarized in
Table 2.
3.Discussion
TCS is the most common type of mandibulofacial dystosis.
This study shows three generations of a family being aﬀected
b yT C S .D u et ov a r i a b l ee x p r e s s i v i t yo ft h eg e n er e s p o n s i b l e
for the TCS, the phenotypic expression of the aﬀected
individuals and obligate carriers varies. Thus the diagnosis
in obligate carriers is diﬃcult. In our study the aﬀected
members can be easily diagnosed as they all have downward
slanting palpebral ﬁssures, hypoplasia of mandible, and
hypoplasia of zygomatic arches. Thus the aﬀected members
havetypicalclinicalfeaturesofT CS.Themodeofinheritance
in the pedigree is consistent with autosomal dominant (AD)
pattern of inheritance. TCS is the most common type of AD
mandibulofacial dysostosis. Various reports show a patient
with TCS and a de novo deletion of region 4p15.32–p14 [26]
a girl with a de novo balanced translocation involving chro-
mosome 5 and 13, t(5;13)(q11;p11) [21] and an association
of TCS and a balanced translocation t(6;16)(p21.31;p13.11)
[18], although unaﬀected family members also were found
to carry translocation. The existence of a similar phenotype
in aﬀected individual with detected chromosomal rearrange-
ments supports the existence of genetic heterogeneity of
TCS/MFD. However, these chromosomal regions may not
be the candidate regions for TCS. It has been shown in a
family with MFD and an apparently balanced translocation
t(6;16)(p21.31;p13.11); another child with MFD had a
normal karyotype, and this translocation did not segregate
with this disease.
To the best of our knowledge, there is no report in the
literature, which shows the concordance between TCS and
3q2 deletion. Cytogenetic ﬁndings in our case show the
deletion in 5q3 and 3q2 within a family which has never
been reported earlier. Deletion in chromosome 5 has been4 Case Reports in Medicine
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Figure 3:(a)G-banded imageofchromosome3and5showingdel(5)(q32-33)del(3q)(q23–25)in II.2.(b) G-banded imageofchromosome
5 showing del(5)(q32-33) III.3. (c) G-banded image of chromosome 5 showing del(5)(q32-33) IV.2. (d) G-banded image of chromosome 5
showingdel(5)(q32-33) in IV.1.
detected in all the aﬀected members whereas deletion in
chromosome 3 has been detected only in one member of the
family. We initially thought that our ﬁndings may possibly
support the genetic heterogeneity, with the 3q2 deletion
causing TCS. However, the detection of 5q3 deletion does
not support this conclusion. One member of the family
(II.2), despite having 3q2 deletion, had 5q3 deletion that
excluded the 3q2 being the candidate region for TCS. The
deleted 3q23–25 region has been mapped for BPES, primary
ovarian failure (POF3), Brucksyndrome 2, autism (AUTS8),
short stature (SHOX2), Asperger syndrome, and Leukemia
(AML,MLF1).Butreviewofseveralreported casesand some
of obligatory features of BPES concluded that it has been
linked to 3q23–25 region in our case. The region contains
a forkhead transcription factor (FOXL2) gene, mutation in
w h i c hc a u s e sB P E S .H o w e v e rB P E Sa l s oh a sb e e nf o u n d
in patients showing 7q deletion which shows that BPES is
also of genetically heterogeneous entity and it may result
from contiguous gene defect [27, 28]. BPES may be with
premature ovarian failure (type I) or without premature
ovarian failure (type II). Blepharophimosis and ptosis are
the most common signs of the BPES whereas less frequently
observed anomalies are telecanthus, microphthalmia, broad
nasal bridge, strabismus, ventricular septal defect, convex
arches of the eyebrows and abnormalities of ﬁnger and toes
or foot deformities. Micrognathia, cleft palate, hearing loss,
and malformed ears are some of the phenotypes which are
common in both TCSand BPES.In ourcase none ofthe spe-
ciﬁc features of BPES were present in the aﬀected members.
The karyotype of aﬀected members shows mosaicism, and
the 3q deletion has been found to be 10% (II.2). It shows
that the number of cells with 3q deletion is very low which
could be another reason for absence of BPES phenotypes.
In summary we propose that we found a novel deletion
at 3q23–25 in this family. The phenotype is consistent with
that of TCS. Screening and detailed genetic analysis of more
patients of TCS should be done to study the alternative
candidate loci for TCS.
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